安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAR 安飞士

盘后交易 02-18 16:56:23 EST

123.30

+1.20

+0.98%

盘后105.80

-17.50-14.19%

16:55 EST

最高126.16	最低122.16	成交量96.24万
今开123.06	昨收122.10	日振幅3.28%
总市值43.40亿	流通市值18.21亿	总股本3,520万
成交额1.19亿	换手率6.52%	流通股本1,477万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAR","market":"US","secType":"STK","nameCN":"安飞士","latestPrice":123.3,"timestamp":1771448400000,"preClose":122.1,"halted":0,"volume":962375,"hourTrading":{"tag":"盘后","latestPrice":105.8,"preClose":123.3,"latestTime":"16:55 EST","volume":61505,"amount":7376613.860950001,"timestamp":1771451703121,"change":-17.5,"changeRate":-0.14193,"amplitude":0.150483},"delay":0,"changeRate":0.009828009828009852,"floatShares":14770456,"shares":35196992,"eps":-59.65909,"marketStatus":"盘后交易","change":1.2,"latestTime":"02-18 16:56:23 EST","open":123.06,"high":126.16,"low":122.155,"amount":119334952.31625001,"amplitude":0.032801,"askPrice":106.72,"askSize":4,"bidPrice":105.01,"bidSize":15,"shortable":3,"etf":0,"ttmEps":-59.65909,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771462800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":122.1,"preHourTrading":{"tag":"盘前","latestPrice":122.1,"preClose":122.1,"latestTime":"09:20 EST","volume":351,"amount":42201.22842,"timestamp":1771424447983,"change":0,"changeRate":0,"amplitude":0.011466},"postHourTrading":{"tag":"盘后","latestPrice":105.8,"preClose":123.3,"latestTime":"16:55 EST","volume":61505,"amount":7376613.860950001,"timestamp":1771451703121,"change":-17.5,"changeRate":-0.14193,"amplitude":0.150483},"volumeRatio":1.365337,"impliedVol":0.606,"impliedVolPercentile":0.6335},"requestUrl":"/m/hq/s/CAR/tweets","defaultTab":"tweets","newsList":[{"id":"2611952901","title":"科济药业-B(02171)与上海金工企业发展签署战略合作协议 投建金山CAR-T细胞治疗产品商业化生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2611952901","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611952901?lang=zh_cn&edition=full","pubTime":"2026-02-13 08:07","pubTimestamp":1770941237,"startTime":"0","endTime":"0","summary":"在此背景下，提升符合国际标准的CAR-T细胞治疗产能成为支撑多个产品商业化落地及增强全球竞争力的核心举措。总体来看，此次合作彰显了本公司稳健的财务规划和对CAR-T细胞治疗产业生态系统的深度布局，也表明该项目高度契合国家及地方的生物医药产业政策，得到了政府层面的高度重视与大力支持。这项战略合作将助力本公司进一步巩固其在全球CAR-T细胞治疗领域的领先地位，同时为股东创造长远价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4022","02171","BK1587","CAR","BK1161","159830","BK4230","BK1585"],"gpt_icon":0},{"id":"1124649550","title":"财报前瞻 ｜安飞士本季度营收预计增长0.98%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1124649550","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124649550?lang=zh_cn&edition=full","pubTime":"2026-02-11 10:45","pubTimestamp":1770777919,"startTime":"0","endTime":"0","summary":"- 上季度预告与实际：EBIT实际5.85亿美元、同比增长37.97%；EPS实际10.11美元、同比增长52.03%；营收实际35.19亿美元、同比增长1.12%. - 本季度预测：营收预计27.38亿美元、同比增长0.98%；EBIT预计0.88亿美元、同比增长239.64%；EPS预计-0.42美元、同比增长36.90%. 安飞士本季度预计营收增长0.98%，对应旅游与商务出行的淡旺季切换，需求呈现结构性的回落。从近期机构观点来看，市场整体偏谨慎，关注淡季盈利与EPS为负的压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 ｜安飞士本季度营收预计增长0.98%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR"],"gpt_icon":0},{"id":"1195423611","title":"CAR集团AI投资难消估值疑虑——市场评论","url":"https://stock-news.laohu8.com/highlight/detail?id=1195423611","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195423611?lang=zh_cn&edition=full","pubTime":"2026-02-10 07:10","pubTimestamp":1770678651,"startTime":"0","endTime":"0","summary":"CAR集团持续加码人工智能领域的投资，但这并未能消除麦格理集团对该技术潜在估值影响的担忧。尽管该投行的分析师认同这家汽车广告平台管理层的观点，即AI能力确实能加速短期产品开发并提升成本效益，但他们对此后的发展前景仍持谨慎态度。\n分析师在给客户的报告中指出，这家澳大利亚公司战略执行良好，短期投资应能支撑其中期增长。然而，外部AI服务商在多大程度上能复制其专业的分类广告能力存在不确定性，加之潜在股价催化因素尚不明确，这使得麦格理对估值发现过程保持警惕。\n麦格理将其目标股价下调27%至28.50澳元，并维持对该股的中性评级。该股在开盘前报26.91澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4230","CAR.AU","BK7503","BK7002","CAR"],"gpt_icon":0},{"id":"2609660445","title":"安飞士盘中异动 下午盘股价大跌5.10%报116.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609660445","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609660445?lang=zh_cn&edition=full","pubTime":"2026-02-06 02:48","pubTimestamp":1770317309,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日02时48分，安飞士股票出现波动，股价急速跳水5.10%。截至发稿，该股报116.62美元/股，成交量21.602万股，换手率0.61%，振幅4.13%。机构评级方面，在所有9家参与评级的机构中，22%的券商给予买入建议，56%的券商给予持有建议，22%的券商给予卖出建议。安飞士股票所在的租赁服务行业中，整体跌幅为1.17%。安飞士致力于服务旅游业高端的商务及休闲细分市场，百捷特则面向重视性价比的客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020602482997a51378&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020602482997a51378&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR","BK4230","BK4022"],"gpt_icon":0},{"id":"2608335603","title":"2025年In Vivo CAR-T竞争格局及BD情况：MNC重金布局，中国药企多点开花迎突破！","url":"https://stock-news.laohu8.com/highlight/detail?id=2608335603","media":"摩熵医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608335603?lang=zh_cn&edition=full","pubTime":"2026-02-03 11:43","pubTimestamp":1770090193,"startTime":"0","endTime":"0","summary":"2025年，这一前沿领域迎来了里程碑式的进展——虹信生物基于mRNA-LNP技术的In Vivo CAR-T候选药物HN2301首次在人体上验证了该技术路径的可行性。这不仅为自身免疫疾病的治疗开辟了新路径，也正式宣告In Vivo CAR-T从实验室加速走向临床应用。据不完全统计，仅2025年一年，全球围绕In Vivo CAR-T的重磅交易金额已超过65亿美元。2026年in vivo CAR-T赛道将持续火热，并且该趋势很有可能有增无减。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203114341a475bdd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203114341a475bdd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1732800096.USD","IE00BJJMRZ35.SGD","LU0320765646.SGD","LU2505996509.AUD","LU0058720904.USD","LU2430703251.USD","LU1244550221.USD","LU1914381329.SGD","IE00BLSP4239.USD","LU1267930813.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0234572021.USD","BK4533","LU1674673691.USD","IE00B2B36J28.USD","LU0122379950.USD","LU2430703178.SGD","BK4568","BK4534","BK4007","IE00BFXG1179.USD","LU0070217475.USD","LU0203345920.USD","SG9999002232.USD","IE00B1BXHZ80.USD","LU1066051811.HKD","LU1244550577.SGD","LU2129689605.HKD","CAR","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU1244550494.USD","LU2592432038.USD","BK4550","IE0002141913.USD","LU0795875086.SGD","LU0345769128.USD","LU1074936037.SGD","BK4504","IE00BVYPNW00.USD","LU0792757196.USD","LU2602419157.SGD","BK4559","IE00BBT3K403.USD","IE00BVYPNV92.GBP","LU1059921491.USD","IE00B19Z3581.USD","LU1066053197.SGD","JNJ"],"gpt_icon":0},{"id":"2605442845","title":"晶泰科技(02228)赋能莱芒生物取得细胞疗法重大成果，以1‰剂量CAR-T实现多位系统性红斑狼疮完全缓解出院","url":"https://stock-news.laohu8.com/highlight/detail?id=2605442845","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605442845?lang=zh_cn&edition=full","pubTime":"2026-01-23 09:54","pubTimestamp":1769133255,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，晶泰科技孵化企业莱芒生物在第 44 届摩根大通医疗健康年会发表演讲，并向全球投资者展示了其极低剂量 CAR-T 疗法的研究者发起临床最新成果。血液瘤与自身免疫疾病临床双重突破在晶泰科技的助力下，莱芒生物开发的代谢增强型 CD19 CAR-T疗法，在自免性疾病和血液瘤领域展现出突破性治疗潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02228","BK1617","BK4230","BK4022","BK1141","CAR"],"gpt_icon":0},{"id":"2605446971","title":"终于有国产CAR-T企业快要扭亏了！传奇生物预计今年实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2605446971","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605446971?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:08","pubTimestamp":1769072934,"startTime":"0","endTime":"0","summary":"在绝大多数国产CAR-T企业苦于商业化挣扎之际，率先出海的传奇生物（LEGN.NS）业绩快要“上岸”了。传奇生物的CAR-T药物合作方强生于当地时间1月21日公布的财报显示，Carvykti（西达基奥仑赛）在2025年实现收入18.88亿美元，较上年同期（9.63亿美元）增长95.9%。西达基奥仑赛是一款用于治疗复发或难治性多发性骨髓瘤的细胞疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601223627442037.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627442037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4230","BK4588","BK4139","BK4505","BK4585","LEGN","BK4022"],"gpt_icon":0},{"id":"2605646854","title":"强生今年营收有望破千亿美元：去年净利增九成，CAR-T收入增95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605646854","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605646854?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:14","pubTimestamp":1769066066,"startTime":"0","endTime":"0","summary":"跨国药企强生交出了营收净利双增的业绩，来自中国的CAR-T疗法销售表现亮眼。当地时间1月21日，美国强生公司公布2025年四季报以及全年财报。2025年第四季度收入245.64亿美元，同比增长9.1%，净利润51.16亿美元，同比增长49.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601223627319570.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627319570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","JNJ"],"gpt_icon":0},{"id":"2605435278","title":"百时美施贵宝 (BMS) CAR-T疗法启动III期临床，治疗自免疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2605435278","media":"细胞治疗前沿","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605435278?lang=zh_cn&edition=full","pubTime":"2026-01-21 09:53","pubTimestamp":1768960424,"startTime":"0","endTime":"0","summary":"近日，美国临床试验收录网显示，百时美施贵宝的 CD19 CAR-T 细胞疗法 Zola-cel启动了首个 Ⅲ 期临床试验，治疗活动性系统性硬化症。Zola-cel是BMS基于NEX-T平台开发的一款CD19 CAR-T细胞疗法，于2020年进入临床阶段。2019年，BMS以740亿美元完成对Celgene的收购，借此将两款关键CAR-T疗法Breyanzi与Abecma纳入其产品管线，正式踏入细胞治疗领域。BMS积极布局，不断强化其在下一代细胞治疗领域的战略纵深。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242652126.USD","LU1032466523.USD","BK4588","BK4134","CAR","LU2360032135.SGD","LU1868836591.USD","LU1571399168.USD","BMY","LU0061475181.USD","LU0306806265.USD","LU1868836914.USD","LU0096364046.USD","BK4585","LU0225284248.USD","III","LU0868494617.USD","LU0882574055.USD","LU0267386448.USD","LU1670711123.USD","LU0225771236.USD","IE00BJJMRZ35.SGD","LU1989771016.USD","LU0985481810.HKD","LU1718418525.SGD","IE0002141913.USD","LU1868837136.USD","LU0306807586.USD","BK4581","LU1261432733.SGD","LU2125154935.USD","LU2133065610.SGD","BK4559","BMS","LU1670710661.SGD","IE00BFTCPJ56.SGD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU1670711040.USD","LU1868836757.USD","LU2125154778.USD","BK4532","BK4534","LU1291159041.SGD","LU0321505868.SGD","BK4007","IE00BSNM7G36.USD","LU1323610961.USD","IE00BFXG1179.USD","LU0321505439.SGD"],"gpt_icon":0},{"id":"2604183102","title":"阿斯利康收购西比曼生物GPC3装甲型CAR-T疗法在中国的剩余权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2604183102","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604183102?lang=zh_cn&edition=full","pubTime":"2026-01-19 15:20","pubTimestamp":1768807256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2236285917.USD","BK4230","LU1829250122.USD","LU0109394709.USD","LU2417539215.USD","LU2462157665.USD","LU2456880835.USD","CAR","AZN","LU0889565916.HKD","BK4585","BK4588","LU0320765992.SGD","BK4568","BK4007","BK4022"],"gpt_icon":0},{"id":"1195653498","title":"WiseTech、REA与CAR集团被视为最能抵御AI威胁的澳大利亚科技媒体股——市场快评","url":"https://stock-news.laohu8.com/highlight/detail?id=1195653498","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195653498?lang=zh_cn&edition=full","pubTime":"2026-01-07 06:54","pubTimestamp":1767740072,"startTime":"0","endTime":"0","summary":"杰富瑞分析师罗杰·塞缪尔指出，在澳大利亚科技与媒体板块中，WiseTech Global、REA集团与CAR集团最具备抵御人工智能竞争威胁的能力。塞缪尔分析认为，软件开发企业WiseTech受到其所在物流行业复杂性的天然壁垒保护。他在研究报告中强调，由新闻集团控股的房地产广告平台REA拥有坚固的数据护城河、强大的品牌影响力以及房产经纪人的高度忠诚度。对于CAR集团，他认为任何试图通过AI技术挑战其地位的汽车广告平台都必须提供更卓越的用户体验，而这一领域正是该龙头企业持续创新的核心战场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR.AU","BK7002","BK7016","BK4022","CAR","WTC.AU","REA.AU","BK4230","BK7503"],"gpt_icon":0},{"id":"2593720654","title":"2025 ASH | 强生公布 CD19/CD20 双靶点 CAR-T 1b 期最新临床进展与生物标志物分析！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593720654","media":"医麦客","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593720654?lang=zh_cn&edition=full","pubTime":"2025-12-24 07:20","pubTimestamp":1766532031,"startTime":"0","endTime":"0","summary":"2025 年 12 月 24 日医麦客新闻 eMedClub News本月 9 日，强生在第 65 届美国血液学会年会上以口头报告形式，更新了其双靶点 CAR-T 疗法 Prizlo-cel的 1b 期临床试验数据及生物标志物关联分析。目前也仅有约 40% 的患者通过现有的单抗原靶向 CD19 CAR-T 细胞疗法获得长期缓解。ORR 达 91%，CR 率 75% 该数据显著优于传统 CD19 CAR-T 历史数据。Grade 3 中位数略高，但 Grade 1 和 Grade 2 中同样有高峰值浓度样本，并未显示 ICANS 严重程度与 CAR-T 细胞扩增有显著关联。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224072631a470912f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224072631a470912f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU2129689431.USD","IE00BFXG1179.USD","LU1059921491.USD","IE00B4R5TH58.HKD","LU0234572021.USD","LU2112291526.USD","LU1280957306.USD","LU0345769128.USD","BK4504","IE00B7SZLL34.SGD","LU0787776722.HKD","JNJ","LU2505996509.AUD","LU1496350502.SGD","LU2505996681.GBP","ASH","LU2750360641.GBP","LU0203347892.USD","LU1057294990.SGD","IE00B19Z3581.USD","CAR","LU0289739699.SGD","LU1778281490.HKD","BK4592","LU0795875086.SGD","LU2463526074.USD","IE00BJT1NW94.SGD","LU1244550577.SGD","LU0234570918.USD","LU2430703095.HKD","IE00BFTCPJ56.SGD","IE00B42XCP33.USD","LU1032955483.USD","LU1162221912.USD","LU2468319806.SGD","LU2750360997.AUD","BK4022","IE00BGHQF631.EUR","LU0070217475.USD","LU0466842654.USD","SG9999002224.SGD","BK4559","LU1023059063.AUD","LU0114720955.EUR","IE00B1BXHZ80.USD","IE0034235303.USD","LU1732799900.SGD","LU1196500208.SGD","BK4534"],"gpt_icon":0},{"id":"2589879103","title":"近半新增药品为一类新药！2025国谈结果公布：五款CAR-T均商保破冰 ，创新药支付迈入“价值时代”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589879103","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589879103?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:08","pubTimestamp":1765094886,"startTime":"0","endTime":"0","summary":"今日上午，在广州白云区举行的2025创新药高质量发展大会上，万众瞩目的年度医保准入大考——2025国谈结果正式揭晓。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20251207/20251207161234_79991.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251207/20251207161234_79991.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4022","BK4230","06978","BK1574","CAR","BK1161","159992"],"gpt_icon":0},{"id":"2589875563","title":"五款CAR-T产品纳入2025年商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589875563","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589875563?lang=zh_cn&edition=full","pubTime":"2025-12-07 13:19","pubTimestamp":1765084748,"startTime":"0","endTime":"0","summary":"北京商报讯12月7日，《商业健康保险创新药品目录（2025年）》正式发布，18家创新药企业的19款药品成功纳入，其中包括五款CAR-T产品。具体来看，包括复星凯瑞的阿基仑赛注射液、药明巨诺的瑞基奥仑赛注射液、驯鹿生物的伊基奥仑赛注射液、合源生物的纳基奥仑赛注射液、以及恺兴生命科技的泽沃基奥仑赛注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512073584556645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584556645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4230","CAR","06978","BK1161","BK4022","BK1574","159992"],"gpt_icon":0},{"id":"2588009570","title":"“抗癌神药”屡登热搜，CAR-T如何从绝症救星走向百万患者？","url":"https://stock-news.laohu8.com/highlight/detail?id=2588009570","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588009570?lang=zh_cn&edition=full","pubTime":"2025-12-04 17:29","pubTimestamp":1764840543,"startTime":"0","endTime":"0","summary":"一家医院血液科诊室内，医生正与一位白血病患者家属低声讨论着治疗可能性，当提到“CAR-T”时，家属眼中刚刚燃起的希望很快又被沉重取代——他们刚刚询问了价格。国内已上市的CAR-T疗法价格普遍在百万元左右。当有人惊叹于“一针清零癌细胞”的神奇疗效时，更多人面对的是它百万级的价格门槛。近期，价格高达百万的“抗癌针”屡屡登上热搜榜单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512043582753914.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512043582753914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2582365624","title":"石药HER2单抗报产，华润三九拿下罕见病创新药，国产CAR-T超8.6亿美元出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365624","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582365624?lang=zh_cn&edition=full","pubTime":"2025-11-11 19:07","pubTimestamp":1762859220,"startTime":"0","endTime":"0","summary":"石药集团帕妥珠单抗上市申请获受理11月11日，CDE官网显示，石药集团递交的帕妥珠单抗注射液上市申请获受理，用于治疗HER2阳性乳腺癌。帕妥珠单抗2012年首次获美国FDA批准上市，2018年首次在中国获批上市。虽然受到生物类似药冲击，但罗氏的帕妥珠单抗在2024年的全球销售额仍高达40.97亿美元。目前，LYL273已获得美国FDA授予的mCRC快速通道指定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-11-11/doc-infwzvxy5623725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0140636845.USD","LU0067412154.USD","BK0183","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1226287792.SGD","LU1226287875.USD","BK1515","LU1226288253.USD","LU1960683339.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","CAR","BK0239","IE00B543WZ88.USD","BK0012","BK1574","LU0880133367.SGD","LU0326950275.SGD","LU0314109678.HKD","IE0008369823.USD","LU2039709279.SGD","000999","LU1813983027.USD","BK0175","BK4230","LU1226288170.HKD","LU0072913022.USD","LU1226287529.USD","LU1951186391.HKD","BK0185","BK1191","IE0008368742.USD","01093","LU0501845795.SGD","IE00B031HY20.USD","BK0028","BK1161","BK1521","LU1993786604.SGD","BK0060","159992","IE00BZ08YS42.EUR","LU1328277881.USD","06978","BK0196","LU1807302812.USD","BK0188","LU1152091168.USD","LU1008478684.HKD"],"gpt_icon":0},{"id":"2582262008","title":"改写“进口依赖”！进博会医疗展区直击：十万转离心机破壁、伽玛刀“中国造”、CAR-T疗法可及｜聚焦2025进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582262008","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582262008?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:04","pubTimestamp":1762765456,"startTime":"0","endTime":"0","summary":"2025年11月5日至10日，中国国际进口博览会（下称“进博会”）在上海如期举行，在1.1馆的医疗器械展馆，《华夏时报》记者仿佛步入一场关乎人类健康的未来图景——海尔生物以数智化方案破解实验室痛点，医科达实现全线产品“中国造”，复星医药则让医疗科技从“治愈”走向“生活”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511103559856257.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511103559856257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4230","BK4022"],"gpt_icon":0},{"id":"2582681142","title":"又一款国产CAR-T上市；上海满13周岁女孩免费接种HPV","url":"https://stock-news.laohu8.com/highlight/detail?id=2582681142","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582681142?lang=zh_cn&edition=full","pubTime":"2025-11-10 08:06","pubTimestamp":1762733164,"startTime":"0","endTime":"0","summary":"政策动向上海：本市满13周岁女孩可免费接种人乳头瘤病毒（HPV）疫苗11月9日，据上海发布官微消息，上海市卫健委介绍，自2025年11月10日起，我国将在现行国家免疫规划疫苗基础上，将人乳头瘤病毒（HPV）疫苗纳入国家免疫规划，组织各地为2011年11月10日以后出生的满13周岁女孩，免费接种2剂次双价HPV疫苗（间隔6个月）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511103559111386.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511103559111386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4230","BK4022","CAR"],"gpt_icon":0},{"id":"2581787771","title":"诺纳生物扩大与Umoja合作 共同推进体内CAR-T细胞疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2581787771","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581787771?lang=zh_cn&edition=full","pubTime":"2025-11-05 23:34","pubTimestamp":1762356856,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺纳生物宣布与Umoja Biopharma11月5日达成一项评估与许可协议。双方计划将诺纳生物的HCAb Harbour Mice平台和NonaCarFxTM平台与Umoja的VivoVecTM平台相结合，共同推进多款体内CAR-T细胞疗法研发。根据协议条款，诺纳生物将有权获得首付款、潜在选择权付款，以及合作项目相关里程碑付款。Umoja将负责所有后续产品的开发和商业化工作。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"294159","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","CAR","BK4022"],"gpt_icon":0},{"id":"2581779056","title":"Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779056","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581779056?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:03","pubTimestamp":1762329780,"startTime":"0","endTime":"0","summary":"Caribou presented findings from trials involving its allogeneic CAR T therapies, which use donor-derived cells rather than a patient’s own cells. These therapies were tested in two separate cancer indications, though specific details regarding efficacy or safety outcomes were not disclosed in the report.Caribou公布了其同种异体CAR T疗法的试验结果，该疗法使用捐赠者来源的细胞而非患者自身的细胞。Meanwhile, Kyverna announced plans to move forward with its CAR T program aimed at treating autoimmune conditions. This marks a shift from the traditional focus of CAR T therapy on oncology and represents an effort to expand the technology’s applications into other therapeutic areas. Both companies continue to explore innovative approaches within this rapidly evolving sector of biotechnology..同时，Kyverna 宣布计划推进其旨在治疗自身免疫性疾病的 CAR T 项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRBU","LENZ","BK4007","CAR","KYTX","BK4139","BK4230","BK4539","BK4022"],"gpt_icon":0}],"profile":{"websiteUrl":"http://avisbudgetgroup.com;ir.avisbudgetgroup.com","stockEarnings":[{"period":"1week","weight":0.0462},{"period":"1month","weight":-0.0281},{"period":"3month","weight":-0.0763},{"period":"6month","weight":-0.1875},{"period":"1year","weight":0.3455},{"period":"ytd","weight":-0.0485}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0127},{"period":"3month","weight":0.0305},{"period":"6month","weight":0.0744},{"period":"1year","weight":0.12},{"period":"ytd","weight":0.0014}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avis Budget Group, Inc.是一家全球领先的车辆租赁和汽车共享服务提供商，通过Avis、Budget和Zipcar运营着业内最受认可的三个品牌。该公司是北美、欧洲、澳大利亚、新西兰和某些地区领先的车辆租赁运营商。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.011725},{"month":2,"riseRate":0.625,"avgChangeRate":0.045153},{"month":3,"riseRate":0.6,"avgChangeRate":0.036708},{"month":4,"riseRate":0.666667,"avgChangeRate":0.02598},{"month":5,"riseRate":0.466667,"avgChangeRate":0.01481},{"month":6,"riseRate":0.533333,"avgChangeRate":0.033428},{"month":7,"riseRate":0.6,"avgChangeRate":0.040059},{"month":8,"riseRate":0.4,"avgChangeRate":-0.00977},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.027276},{"month":10,"riseRate":0.666667,"avgChangeRate":0.119671},{"month":11,"riseRate":0.666667,"avgChangeRate":0.07647},{"month":12,"riseRate":0.4,"avgChangeRate":-0.047503}],"exchange":"NASDAQ","name":"安飞士","nameEN":"Avis Budget"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安飞士,CAR,安飞士股票,安飞士股票老虎,安飞士股票老虎国际,安飞士行情,安飞士股票行情,安飞士股价,安飞士股市,安飞士股票价格,安飞士股票交易,安飞士股票购买,安飞士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}